Friday, February 27, 2015

Neurite Outgrowth Assays-96 Well Plates

Fast, Effective and Data Rich!

Our Customers' are reporting great results using our hN2 Primary Human Neurons. We are seeing a natural evolution for high content to high throughput screening. This is because our human neuron culturing kits are proving pure and potent (sample pubs).

Here's some customer data using hN2™ Human Neurons High Throughput Screening (HTS) Kit:

Image: Neurite Outgrowth Assay in 96 Well Plate using hN2 Neurons-Blue – Nuclear staining; Green – Neurite and cell body staining.

Want to learn more? Contact me directly at pshuster@neuromics.com or 612-801-1007. Thank you. Pete Shuster, CEO and Owner, Neuromics.

Wednesday, February 25, 2015

Neuromics-ArunA Biomedical Partnership

We are Closer than Ever!

I spent the past several days meeting with Ms. Tracey Stice (COO), Dr. Steven Stice (President and CSO) and Ms. Joy Clark (Sales and Marketing Manager) at ArunA HQ in Athens, GA. The objective of the meeting was to finalize plans for our Strategic Selling Partnership. This partnership enables us to open up more cell based assay solutions to current and future Customers involved in neuro-diseases/disorders research and drug discovery.
The Aruna Team

...And the news gets better. By combining our expertise and experience, we are now well positioned to to:
  1. Shape new solutions and services that would more tightly aligned with your unique requirements
  2. Communicate how other labs within your organization are using our solutions and look for ways to leverage this.
  3. Track buying volume so we can give favorable pricing based on purchase made in total by your organization vs specific groups.
We will be working even harder to make sure you that you are satisfied with the value we bring to you and your team. Wondering what we can do for you today? You can contact me directly 612-801-1007 or pshuster@neuromics.com. Thank you. Pete Shuster, CEO, Neuromics AND ArunA Biomedical Strategic Selling Partner.

Saturday, February 21, 2015

i-Fect Delivers siRNA in vitro and in vivo

Gene Expression Analysis for Studying Stroke

We have posted over 35 publications that reference use of our i-Fect Transfection Kit to deliver siRNA, miRNA and shRNA in vitro and in vivo. Results documented in these publications prove that this kit is both non-toxic and delivers ultra-high transfection efficiency.

i-Fect Data Example


Figure. The effects of HDAC2 siRNA Infusion into the CeA of P rats on voluntary ethanol consumption as measured by the two-bottle free choice paradigm. Monitoring the voluntary ethanol consumption of alcohol-preferring (P) rats via the two bottle free choice paradigm following infusion of vehicle or histone deacetylase isoform 2 (HDAC2) siRNA into the central amygdala (CeA) demonstrates that high HDAC2 levels may mediate the high alcohol drinking behaviors of P rats. P rats were given access to water and 7% ethanol followed by water and 9% ethanol. On the sixth day of ethanol access P rats received infusion of vehicle or HDAC2 siRNA and consumption of water and 9% ethanol were monitored for sevnfusion. Total fluid intake did not significantly differ between the groups. Values are represented as the mean ± SEM of the ethanol consumption (g / kg / day) and total fluid intake (mL) plotted daily for n=6 rats per treatment group. *Significantly different between the groups.SACHIN MOONAT. The Role of Amygdaloid Chromatin and Synaptic Remodeling in Anxiety and Alcoholism. THESIS Submitted as partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate College of the University of Illinois at Chicago, 2014.

Here's yet another recent publication highlighting use of i-Fect:

In this study data suggest the protective effects of EPO on NUV injuries are highly associated with the increase of p-Cx43, which improves GJIC to reduce neurotoxic substances: Ziyi Zhoua, Xiaobai Weib, Jun Xiang, Junpeng Gao, Lixin Wang, Jinsong You, Yefeng Cai , Dingfang Caid. Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43. Biochemical and Biophysical Research Communications. doi:10.1016/j.bbrc.2015.02...The strands were incubated at 90°C for 5 min and then at 37°C for 1 h. SiRNA was prepared immediately before administration by mixing the RNA solution (1 μg/μl in annealing buffer) with the transfection reagent i-Fect (v/v: 1/3; Neuromics, Edina, MN, USA) to a final siRNA ...

Highlights
•EPO has protective effects on ischemic NVU injuries.
•EPO up-regulates phosphorylation of Cx43, not total Cx43.
•EPO's protective effects on NUV injuries are p-Cx43-GJIC dependent.

Wednesday, February 11, 2015

Proven and Published Sandwich ELISA Kits

Growing Catalog of ELISA Kits

We are partnering with RayBiotech to manufacture our ELISA Kits. They have proven valuable additions to our Cell Based Assay solutions.

Neuromics has been built on a foundation of quality. RayBiotech's commitment to quality includes compliance to GLP/GMP FDA and ISO9000 regulations.
ELISA Kits Sample Data

Figure: Induction of proinflammatory cytokines is attenuated in CX3CL1−/− mice expressing sFKN. TNFα and IL-1β concentrations were measured using standard ELISA techniques for VM lysates. a, TNFα concentrations were upregulated following MPTP administration (three-way ANOVA; F(1, 23) = 18.36, ★★★p < 0.001). Comparatively, CX3CL1−/− mice expressing sFKN in the SNpc had significantly lower concentrations of TNFα relative to mFKN (Tukey's HSD; ***p < 0.001) and GFP (Tukey's HSD; ###p < 0.001) expressing mice. There were no significant differences between sFKN and WT-MPTP (Tukey's HSD; p = 0.384) or mFKN and GFP (Tukey's HSD; p = 0.773). b, The IL-1β concentrations in the VM were significantly upregulated for mice exposed to MPTP (three-way ANOVA; F(1, 23) = 11.97, ★★★p = 0.002). Similar to the pattern of TNFα, IL-1β concentrations in CX3CL1−/− mice expressing sFKN were significantly blunted compared to both mFKN (Tukey's HSD; ***p = 0.001) and GFP (Tukey's HSD; ###p < 0.001). As was observed with TNFα, there were no significant differences in IL-1β concentrations between WT-MPTP and sFKN (Tukey's HSD; p = 0.785) or mFKN and GFP (Tukey's HSD; p = 0.845) expressing mice. Data are presented as the mean ± SEM.

Questions? Please contact me directly, Pete Shuster, CEO and Owner, 612-801-1007 or pshuster@neuromics.com. Thank you.

Saturday, February 07, 2015

Your Feedback Matters

Our Solutions Must Work

We take our ability to serve you very seriously. We use bird-eye to make sure each and every one of our customers are pleased with results. If you are not happy, we do everything we can to fix your issue. This includes replacement and refunds:
Should you ever have questions or issues, I am at your "beck and call". Do not hesitate to contact me directly. Pete Shuster, CEO and Owner, Neuromics, 612-801-1007 or pshuster@neuromics.com. Thank you!